HD Insights™

Volume 2

Issue link: http://www.e-digitaleditions.com/i/56063

Contents of this Issue


Page 6 of 7

HD INSIGHTS Meet the Journal VITAL SIGNS NAME: Journal of Huntington's Disease EDITORS-IN-CHIEF:!Blair Leavitt, MD ! ! ! Leslie Thompson, PhD PUBLISHER: IOS Press SUBSCRIPTION MODEL: Subscription and open access SUBMISSION SITE: http://www.iospress.nl/journal/journal-of-huntingtons-disease/. Please email info@isopress.nl with questions regarding manuscript submission. Blair Leavitt, MD Leslie Thompson, PhD The Journal of Huntington's Disease launches in early 2012. The journal has a renowned editorial board and is currently accepting papers for peer review. Manuscripts will be published online and in quarterly print publications. At the 2011 Huntington Disease Clinical Research Symposium in Indianapolis, IN, Dr. Blair Leavitt sat down with HD Insights to discuss the new journal. Dr. Leslie Thompson also shared her thoughts on the new journal via email correspondence. INSIGHTS: Why a new journal for HD? THOMPSON: We want to have a single source bringing together all the various aspects of basic and clinical HD research. The field has grown significantly and we feel this would be of great benefit to HD researchers, clinicians, and other HD community members. LEAVITT: We think there is a niche and a need for this. Given the number of publications each year in the field of HD, it was time for a journal dedicated specifically to HD. INSIGHTS: How will the Journal of Huntington's Disease be different from Movement Disorders, or Neurology or other journals that publish articles related to HD? LEAVITT: It will be specifically for HD and related disorders. I want to clarify that we will cover related disorders such as other polyglutamine disorders. THOMPSON: The journal will also include meeting announcements, editorials, special interest pieces and reviews. INSIGHTS: Why has it taken so long for a journal to be developed focused on HD? LEAVITT: This journal has evolved out of sister journals that have really been quite successful, such as the Journal of Alzheimer's Disease and the Journal of Parkinson's Disease. Dr. Patrik Brundin, the editor-in-chief of the Journal of Parkinson's Disease, was the first to suggest that we should do this for HD. We think the field is ready for it. THOMPSON: The field has grown over time to include hundreds of researchers, and interest in pharmaceutical development has grown. With the known mutation for the disease comes the opportunity for HD to serve as a paradigm for other neurodegenerative diseases. HD Insights, Vol. 2 Copyright © Huntington Study Group 2012. All rights reserved. 7

Articles in this issue

Links on this page

Archives of this issue

view archives of HD Insights™ - Volume 2